Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
基本信息
- 批准号:10630249
- 负责人:
- 金额:$ 53.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-25 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:Accident and Emergency departmentAdmission activityAffectAllergensAllergicAllergic DiseaseAmino AcidsAntibodiesAntibody RepertoireAntibody ResponseAsthmaAwardB-Lymphocyte EpitopesB-LymphocytesBindingBiological AssayCanis familiarisCaspaseCellsCharacteristicsChildClinical ResearchComplexCrystallizationDataData SetDatabasesDermatophagoides farinae antigen f 1Dermatophagoides pteronyssinus antigen p 1Dermatophagoides pteronyssinus antigen p 2DevelopmentDictyopteraDiseaseEngineeringEpitope MappingEpitopesFelis catusFundingFutureGoalsGrantHealthHomologous GeneHouse Dust Mite AllergensHumanHybridomasHypersensitivityIgEImmuneImmune responseImmunoassayImmunoglobulin GImmunologicsImmunotherapeutic agentImmunotherapyInnate Immune SystemLibrariesLightMammalian CellMapsMediatorMitesMolecularMolecular ConformationMonoclonal AntibodiesMultiple MyelomaMusMutateNuclear Magnetic ResonancePatientsPersonsPhage DisplayPhasePlayPrevalencePropertyPulmonary InflammationPyroglyphidaeRecombinant AntibodyRecombinant ProteinsRecombinantsReportingRisk FactorsRoleSite-Directed MutagenesisSourceSpecificityStructureT-Cell ActivationT-Cell ProliferationT-LymphocyteTechnologyTestingTimeToll-like receptorsVaccine DesignVaccinesVariantX-Ray Crystallographyasthmaticasthmatic patientcockroach allergencombinatorialcytokinedesigndust mite allergyimmunoreactivityimmunotherapy trialsimpaired capacityimprovedin vivoindoor allergeninner cityinnovationlipopolysaccharide-binding proteinmutantrational designresponsethree dimensional structuretoolvaccine immunotherapy
项目摘要
TITLE: Antigenic determinants of asthma-associated allergens for design of immunotherapy
PROJECT SUMMARY/ABSTRACT
House dust mite allergy is an important health problem worldwide, affecting up to 85% of asthmatic children,
and a risk factor for emergency room admission with asthma. Group 1 and 2 mite allergens account for more
than 50% of total house dust mite specific IgE reactivity in mite allergic patients. Recently, Der p 23 has also
been identified as a major mite allergen, but its contribution to the total house dust mite specific IgE is small.
Group 1 allergens are cysteine proteases that contribute to lung inflammation in asthma, whereas group 2
allergens are lipopolysaccharide binding proteins. Der p 2 has been reported to mimic a human structural-
homolog that activates the innate immune system through toll like receptors. Despite these important molecular
differences between proteolytic group 1 and non-proteolytic group 2, a high IgE prevalence of 83% to allergens
from both groups has been observed in mite allergic patients in the U.S. However, the IgE repertoire and
antigenic determinants associated with these two major allergens are not known. The main goal of this
project is to investigate the antigenic structure of both groups of mite allergens for the design of
immunotherapy. Allergen-specific IgE monoclonal antibodies (mAb) will be produced for the first time with the
correct pairing of the heavy and light chains as they occur in vivo, using hybridomas obtained from the fusion of
B cells from allergic donors with a myeloma partner that confers immortality. Allergens will be co-crystallized
with recombinant IgE antibody constructs. The key amino acids involved in IgE antibody binding will be
identified and modified. The specific aims are: 1) Isolation of IgE mAb specific for asthma-associated allergens
by hybridoma technology; 2) mapping of antigenic determinants on groups 1 and 2 dust mite allergens by X-ray
crystallography and analysis of IgE antibody binding epitopes; and 3) site-directed mutagenesis of IgE antibody
epitopes for expression of hypoallergenic mutants with T cell reactivity as candidates for immunotherapy. An
analysis of the association between mite allergen-specific IgE antibodies from the human repertoire and the
epitopes recognized by these IgE antibodies will be performed with the information obtained in the first two
aims. Aim #2 will generate experimental data sets of three-dimensional structures of B-cell epitopes, which are
currently missing in databases used for developing tools for B cell epitope prediction. Most importantly, this
project will define IgE antibody responses to mite allergens and will provide the structural basis for rational
design of hypoallergens. In Aim #3, IgE antibody binding to the epitope mutants will be analyzed by
immunoassays and cell mediator release assays, and T cell reactivity will be evaluated. Mutants will be
compared and hypoallergenic forms will be selected for the design of vaccines for immunotherapy of mite
allergy.
题目:哮喘相关过敏原的抗原决定因素用于免疫治疗设计
项目成果
期刊论文数量(52)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Serological, genomic and structural analyses of the major mite allergen Der p 23.
主要螨过敏原p23的血清学,基因组和结构分析。
- DOI:10.1111/cea.12680
- 发表时间:2016-02
- 期刊:
- 影响因子:0
- 作者:Mueller GA;Randall TA;Glesner J;Pedersen LC;Perera L;Edwards LL;DeRose EF;Chapman MD;London RE;Pomés A
- 通讯作者:Pomés A
100 Years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology.
100 年后:庆祝 X 射线晶体学对过敏和临床免疫学的贡献。
- DOI:10.1016/j.jaci.2015.05.016
- 发表时间:2015
- 期刊:
- 影响因子:0
- 作者:Pomés,Anna;Chruszcz,Maksymilian;Gustchina,Alla;Minor,Wladek;Mueller,GeoffreyA;Pedersen,LarsC;Wlodawer,Alexander;Chapman,MartinD
- 通讯作者:Chapman,MartinD
Biological activity of human IgE monoclonal antibodies targeting Der p 2, Fel d 1, Ara h 2 in basophil mediator release assays.
- DOI:10.3389/fimmu.2023.1155613
- 发表时间:2023
- 期刊:
- 影响因子:7.3
- 作者:Pena-Castellanos, Glorismer;Smith, Bryan R. E.;Pomes, Anna;Smith, Scott A.;Stigler, Maria A.;Widauer, Hannah L.;Versteeg, Serge A.;van Ree, Ronald;Chapman, Martin D.;Aglas, Lorenz
- 通讯作者:Aglas, Lorenz
A robust method for the estimation and visualization of IgE cross-reactivity likelihood between allergens belonging to the same protein family.
- DOI:10.1371/journal.pone.0208276
- 发表时间:2018
- 期刊:
- 影响因子:3.7
- 作者:Chruszcz M;Kapingidza AB;Dolamore C;Kowal K
- 通讯作者:Kowal K
Characterization of an anti-Bla g 1 scFv: epitope mapping and cross-reactivity.
- DOI:10.1016/j.molimm.2014.02.003
- 发表时间:2014-06
- 期刊:
- 影响因子:3.6
- 作者:Mueller GA;Ankney JA;Glesner J;Khurana T;Edwards LL;Pedersen LC;Perera L;Slater JE;Pomés A;London RE
- 通讯作者:London RE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN D. CHAPMAN其他文献
MARTIN D. CHAPMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN D. CHAPMAN', 18)}}的其他基金
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
- 批准号:
8086141 - 财政年份:2010
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
- 批准号:
10413107 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
- 批准号:
8132855 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
用于免疫治疗设计的哮喘相关过敏原的抗原决定因素。
- 批准号:
8960085 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
- 批准号:
10196971 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
用于免疫治疗设计的哮喘相关过敏原的抗原决定因素。
- 批准号:
9067975 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
- 批准号:
7726352 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
用于免疫治疗设计的哮喘相关过敏原的抗原决定因素。
- 批准号:
9540201 - 财政年份:2009
- 资助金额:
$ 53.79万 - 项目类别:














{{item.name}}会员




